Matthew Vincent Dolan - Sep 1, 2023 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
SVP Corporate Strategy-Develop
Signature
By: Jereme Sylvain For: Matthew Dolan
Stock symbol
DXCM
Transactions as of
Sep 1, 2023
Transactions value $
-$5,730
Form type
4
Date filed
9/1/2023, 06:40 PM
Previous filing
Mar 17, 2023
Next filing
Mar 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Sale -$5.73K -56 -0.17% $102.32 33.6K Sep 1, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. he shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
F2 Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.